{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:40:46Z","timestamp":1791636046085,"version":"4.3.4"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Fonds of Regional Development"},{"name":"Ministry for Science, Research and Cultural Affairs of Brandenburg through the grant of the joint project"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.tox.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,27]],"date-time":"2018-11-27T13:01:47Z","timestamp":1543323707000},"page":"37-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4"],"prefix":"10.1016","volume":"412","author":[{"given":"Susanne","family":"Steinbrecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalie","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Uwe","family":"Schmidtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Scheibner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kr\u00fcger-Genge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kammerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Heiner","family":"K\u00fcpper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tox.2018.11.008_bib0005","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/282615a0","article-title":"Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line","volume":"282","author":"Aden","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.tox.2018.11.008_bib0010","first-page":"250","article-title":"Formation of the cytotoxic aldehyde acrolein during in vitro degradation of cyclophosphamide","volume":"233","author":"Alarcon","year":"1971","journal-title":"Nature"},{"key":"10.1016\/j.tox.2018.11.008_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1124\/dmd.105.006759","article-title":"Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells","volume":"34","author":"Aninat","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2018.11.008_bib0020","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/0378-4347(94)00462-E","article-title":"Measurement of 4-hydroxycyclophosphamide in serum by reversed-phase high-performance liquid chromatography","volume":"663","author":"Belfayol","year":"1995","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.tox.2018.11.008_bib0025","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1128\/MCB.20.18.6695-6703.2000","article-title":"DNA excision repair and DNA damage-induced apoptosis are linked to Poly(ADP-ribosyl)ation but have different requirements for p53","volume":"20","author":"Beneke","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tox.2018.11.008_bib0030","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3109\/00498254.2012.675093","article-title":"Generation of proliferating human hepatocytes using upcyte\u00ae technology: characterisation and applications in induction and cytotoxicity assays","volume":"42","author":"Burkard","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tox.2018.11.008_bib0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/0006-291X(90)91195-X","article-title":"Transforming growth-factor-beta (TGF-beta) inhibits albumin synthesis in normal human hepatocytes and in hepatoma HepG2 cells","volume":"171","author":"Busso","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tox.2018.11.008_bib0040","first-page":"21","article-title":"Effect of O6-Benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in chinese Hamster ovary cells","volume":"1","author":"Cai","year":"2001","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tox.2018.11.008_bib0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1517\/17425255.2.2.183","article-title":"Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies","volume":"2","author":"Castell","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tox.2018.11.008_bib0050","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1021\/acs.chemrestox.7b00025","article-title":"Evaluation of DILI predictive hypotheses in early drug development","volume":"30","author":"Chan","year":"2017","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2018.11.008_bib0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00008571-199706000-00006","article-title":"Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation","volume":"7","author":"Chang","year":"1997","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.tox.2018.11.008_bib0060","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes","volume":"53","author":"Chang","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0065","first-page":"1946","article-title":"Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines","volume":"57","author":"Chang","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0070","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/tcm.1770090403","article-title":"Cell cycle alterations and cell death in cyclophosphamide teratogenesis","volume":"9","author":"Chernoff","year":"1989","journal-title":"Teratog., Carcinog. Mutagen."},{"key":"10.1016\/j.tox.2018.11.008_bib0075","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1021\/tx500504n","article-title":"Prediction of drug-induced liver injury in HepG2 cells cultured with human liver microsomes","volume":"28","author":"Choi","year":"2015","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tox.2018.11.008_bib0080","first-page":"1121","article-title":"Alkylating properties of phosphoramide mustard","volume":"36","author":"Colvin","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0085","first-page":"5029","article-title":"Cytotoxicity, DNA cross-linking, and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemia cells","volume":"46","author":"Crook","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0090","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4419-6199-0_9","article-title":"Analysis of cellular DNA content by flow and laser scanning cytometry","volume":"676","author":"Darzynkiewicz","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tox.2018.11.008_bib0095","first-page":"63","article-title":"DNA repair, DNA synthesis and cell cycle delay in human lymphoblastoid cells differentially sensitive to the cytotoxic effects of nitrogen mustard","volume":"132","author":"Dean","year":"1984","journal-title":"Mutat. Res. Repair Rep."},{"key":"10.1016\/j.tox.2018.11.008_bib0100","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2165\/00003088-200342020-00004","article-title":"Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies","volume":"42","author":"Donato","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.tox.2018.11.008_bib0105","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2174\/1389200211314090002","article-title":"Hepatic cell lines for drug hepatotoxicity testing: limitations and strategies to upgrade their metabolic competence by gene engineering","volume":"14","author":"Donato","year":"2013","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.tox.2018.11.008_bib0110","doi-asserted-by":"crossref","first-page":"10614","DOI":"10.1093\/nar\/gkx715","article-title":"H2AX facilitates classical non-homologous end joining at the expense of limited nucleotide loss at repair junctions","volume":"45","author":"Feng","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0115","doi-asserted-by":"crossref","first-page":"146S","DOI":"10.1002\/j.1875-9114.1997.tb03817.x","article-title":"An overview of cyclophosphamide and ifosfamide pharmacology","volume":"17","author":"Fleming","year":"1997","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tox.2018.11.008_bib0120","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.tiv.2011.09.015","article-title":"Cytotoxicity of 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione (DCPT) and analogues in wild type and CYP3A4 stably transfected HepG2 cells","volume":"25","author":"Frederick","year":"2011","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tox.2018.11.008_bib0125","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.taap.2014.11.017","article-title":"Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells","volume":"282","author":"Ganesan","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2018.11.008_bib0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10565-011-9208-4","article-title":"Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins","volume":"28","author":"Gerets","year":"2012","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.tox.2018.11.008_bib0135","first-page":"1286","article-title":"The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI)","volume":"13","author":"Ghallab","year":"2014","journal-title":"EXCLI J."},{"key":"10.1016\/j.tox.2018.11.008_bib0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00228-003-0590-6","article-title":"Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes","volume":"59","author":"Griskevicius","year":"2003","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.tox.2018.11.008_bib0145","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cbi.2006.12.003","article-title":"The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics","volume":"168","author":"Guillouzo","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tox.2018.11.008_bib0150","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cbin.10574","article-title":"Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures","volume":"40","author":"Herzog","year":"2016","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.tox.2018.11.008_bib0155","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JCB-15002","article-title":"Generation of cytochrome P450 3A4-overexpressing HepG2 cell clones for standardization of hepatocellular testosterone 6\u00fc-hydroxylation activity","volume":"1","author":"Herzog","year":"2015","journal-title":"J. Cell. Biotechnol."},{"key":"10.1016\/j.tox.2018.11.008_bib0160","first-page":"2278","article-title":"Synthesis of 4-Hydroperoxy derivatives of Ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo","volume":"36","author":"Hohorst","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0165","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1124\/dmd.110.037077","article-title":"Development of a highly sensitive cytotoxicity assay system for CYP3A4-Mediated metabolic activation","volume":"39","author":"Hosomi","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2018.11.008_bib0170","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0006-2952(99)00410-4","article-title":"Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide","volume":"59","author":"Huang","year":"2000","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tox.2018.11.008_bib0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JCB-15019","article-title":"Chronic ethanol treatment depletes glutathione regeneration capacity in hepatoma cell line HepG2","volume":"1","author":"Kade","year":"2016","journal-title":"J. Cell. Biotechnol."},{"key":"10.1016\/j.tox.2018.11.008_bib0180","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.tiv.2015.02.011","article-title":"The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death","volume":"29","author":"Kamalian","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.tox.2018.11.008_bib0185","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3233\/JCB-179012","article-title":"Human hepatocyte systems for in vitro toxicology analysis","volume":"3","author":"Kammerer","year":"2018","journal-title":"J. Cell. Biotechnol."},{"key":"10.1016\/j.tox.2018.11.008_bib0190","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1124\/dmd.107.020016","article-title":"Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies","volume":"36","author":"Kanebratt","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2018.11.008_bib0195","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/toxsci\/57.1.6","article-title":"The molecular effects of acrolein","volume":"57","author":"Kehrer","year":"2000","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tox.2018.11.008_bib0200","first-page":"305","article-title":"\u03b3-H2AX-a novel biomarker for DNA double-strand breaks","volume":"22","author":"Kuo","year":"2008","journal-title":"In Vivo"},{"key":"10.1016\/j.tox.2018.11.008_bib0205","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijheh.2007.04.004","article-title":"Ethanol enhanced the genotoxicity of acrylamide in human, metabolically competent HepG2 cells by CYP2E1 induction and glutathione depletion","volume":"211","author":"Lamy","year":"2008","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"10.1016\/j.tox.2018.11.008_bib0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/abbi.1998.0615","article-title":"Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal Tolbutamide,S-Mephenytoin, and omeprazole hydroxylations","volume":"353","author":"Lasker","year":"1998","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.tox.2018.11.008_bib0215","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nbt.3377","article-title":"Long-term culture and expansion of primary human hepatocytes","volume":"33","author":"Levy","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.tox.2018.11.008_bib0220","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3892\/br.2015.481","article-title":"Study of the in vitro cytotoxicity testing of medical devices","volume":"3","author":"Li","year":"2015","journal-title":"Biomed. Rep."},{"key":"10.1016\/j.tox.2018.11.008_bib0225","first-page":"830","article-title":"Conversion of 4-Hydroperoxycyclophosphamide and 4-Hydroxycyclophosphamide to Phosphoramide Mustard and acrolein mediated by bifunctional catalysts","volume":"42","author":"Low","year":"1982","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0230","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.vascn.2010.04.013","article-title":"HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro","volume":"63","author":"Lubberstedt","year":"2011","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.tox.2018.11.008_bib0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1677\/joe.1.07087","article-title":"Calpain inhibition impairs glycogen syntheses in HepG2 hepatoma cells without altering insulin signaling","volume":"193","author":"Meier","year":"2007","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.tox.2018.11.008_bib0240","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.taap.2012.09.021","article-title":"Acrolein cytotoxicity in hepatocytes involves endoplasmic reticulum stress, mitochondrial dysfunction and oxidative stress","volume":"265","author":"Mohammad","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2018.11.008_bib0245","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/CH-189120","article-title":"ATP-based cell viability assay is superior to trypan blue exclusion and XTT assay in measuring cytotoxicity of anticancer drugs Taxol and Imatinib, and proteasome inhibitor MG-132 on human hepatoma cell line HepG2","volume":"69","author":"Nowak","year":"2018","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.tox.2018.11.008_bib0250","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0076-6879(08)01606-6","article-title":"DNA damage response and apoptosis","volume":"446","author":"Plesca","year":"2008","journal-title":"Meth. Enzymol."},{"key":"10.1016\/j.tox.2018.11.008_bib0255","first-page":"4229","article-title":"Oxidation of cyclophosphamide to 4-Hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes","volume":"57","author":"Ren","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0260","series-title":"Assay Guidance Manual","article-title":"Cell viability assays","author":"Riss","year":"2004"},{"key":"10.1016\/j.tox.2018.11.008_bib0265","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/00498250210128675","article-title":"Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells","volume":"32","author":"Rodr\u00edguez-Antona","year":"2002","journal-title":"Xenobiotica"},{"key":"10.1016\/j.tox.2018.11.008_bib0270","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.tox.2018.11.008_bib0275","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0090-9556(24)15302-0","article-title":"Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-Expressed activities and liver microsomal P-450 profiles","volume":"27","author":"Roy","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2018.11.008_bib0280","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.taap.2010.01.012","article-title":"Measuring and modeling of binary mixture effects of pharmaceuticals and nickel on cell viability\/cytotoxicity in the human hepatoma derived cell line HepG2","volume":"244","author":"Rudzok","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tox.2018.11.008_bib0285","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0027-5107(95)00246-4","article-title":"Development and validation of alternative metabolic systems for mutagenicity testing in short-term assays","volume":"353","author":"Rueff","year":"1996","journal-title":"Mutat. Res. Mol. Mech. Mutagen."},{"key":"10.1016\/j.tox.2018.11.008_bib0290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/cbic.200400287","article-title":"DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses","volume":"6","author":"Sch\u00e4rer","year":"2005","journal-title":"ChemBioChem."},{"key":"10.1016\/j.tox.2018.11.008_bib0295","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.mrfmmm.2013.07.007","article-title":"Double strand break repair functions of histone H2AX","volume":"750","author":"Scully","year":"2013","journal-title":"Mutat. Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0300","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0163-7258(88)90004-6","article-title":"Metabolism of oxazaphosphorines","volume":"37","author":"Sladek","year":"1988","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tox.2018.11.008_bib0305","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.gene.2015.08.009","article-title":"Pitfalls of the MTT assay: direct and off-target effects of inhibitors can result in over\/underestimation of cell viability","volume":"574","author":"Stepanenko","year":"2015","journal-title":"Gene"},{"key":"10.1016\/j.tox.2018.11.008_bib0310","first-page":"2723","article-title":"Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial","volume":"47","author":"Struck","year":"1987","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0315","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-61779-080-5_19","article-title":"Cellular chemosensitivity assays: an overview","volume":"731","author":"Sumantran","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tox.2018.11.008_bib0320","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00204-013-1012-x","article-title":"HepG2 cells simultaneously expressing five P450 enzymes for the screening of hepatotoxicity: identification of bioactivable drugs and the potential mechanism of toxicity involved","volume":"87","author":"Tolosa","year":"2013","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tox.2018.11.008_bib0325","first-page":"37","article-title":"Decay of gamma-H2AX foci correlates with potentially lethal damage repair and P53 status in human colorectal carcinoma cells","volume":"19","author":"Van Oorschot","year":"2014","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.tox.2018.11.008_bib0330","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the intersections between metabolism and Cancer biology","volume":"168","author":"Vander Heiden","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tox.2018.11.008_bib0335","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ejps.2004.07.006","article-title":"Substrates and inhibitors of efflux proteins interfere with the MTT assay in cells and may lead to underestimation of drug toxicity","volume":"23","author":"Vellonen","year":"2004","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.tox.2018.11.008_bib0340","first-page":"2515","article-title":"Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production","volume":"51","author":"Vistica","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.tox.2018.11.008_bib0345","article-title":"Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols","volume":"5","author":"Wang","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tox.2018.11.008_bib0350","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0090-9556(24)15373-1","article-title":"CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes","volume":"28","author":"Wester","year":"2000","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2018.11.008_bib0355","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.tiv.2007.05.014","article-title":"Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells","volume":"21","author":"Westerink","year":"2007","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tox.2018.11.008_bib0360","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1124\/dmd.31.8.1035","article-title":"Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties","volume":"31","author":"Wilkening","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tox.2018.11.008_bib0365","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cyto.a.22350","article-title":"Fully automated analysis of chemically induced gammaH2AX foci in human peripheral blood mononuclear cells by indirect immunofluorescence","volume":"83","author":"Willitzki","year":"2013","journal-title":"Cytometry A"},{"key":"10.1016\/j.tox.2018.11.008_bib0370","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tiv.2018.01.019","article-title":"Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury","volume":"48","author":"Xu","year":"2018","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.tox.2018.11.008_bib0375","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1538\/expanim.17-0048","article-title":"Effects of ketoconazole on cyclophosphamide metabolism: evaluation of CYP3A4 inhibition effect using the in vitro and in vivo models","volume":"67","author":"Yang","year":"2018","journal-title":"Exp. Anim."},{"key":"10.1016\/j.tox.2018.11.008_bib0380","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0887-2333(01)00011-X","article-title":"Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology","volume":"15","author":"Yoshitomi","year":"2001","journal-title":"Toxicol. Vitr."},{"key":"10.1016\/j.tox.2018.11.008_bib0385","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mrgentox.2005.12.004","article-title":"DNA damage evaluated by \u03b3H2AX foci formation by a selective group of chemical\/physical stressors","volume":"604","author":"Zhou","year":"2006","journal-title":"Mutat. Res."}],"container-title":["Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X18306206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300483X18306206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T23:38:57Z","timestamp":1759534737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300483X18306206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":77,"alternative-id":["S0300483X18306206"],"URL":"https:\/\/doi.org\/10.1016\/j.tox.2018.11.008","relation":{},"ISSN":["0300-483X"],"issn-type":[{"value":"0300-483X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4","name":"articletitle","label":"Article Title"},{"value":"Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tox.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}